81 related articles for article (PubMed ID: 30534880)
1. [Interferon Lambda 4 RS12979860 C>T polymorphism is not associated with liver fibrosis in patients with hepatitis C].
Brahm J; Urzúa A; Poniachik J; Cáceres DD; Carreño L; Venegas M
Rev Med Chil; 2018 Jul; 146(7):823-829. PubMed ID: 30534880
[TBL] [Abstract][Full Text] [Related]
2. Interferon-λ rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population.
Rauff B; Amar A; Chudhary SA; Mahmood S; Tayyab GUN; Hanif R
Arch Virol; 2021 Apr; 166(4):1047-1056. PubMed ID: 33528661
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
[TBL] [Abstract][Full Text] [Related]
4. The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients.
Shridhar Gulati R; Wimalanathan T; Norheim Andersen S; Isaksen K; Lagging M; Midgard H; Moghaddam A; Dalgard O
Scand J Gastroenterol; 2019 Sep; 54(9):1172-1175. PubMed ID: 31479286
[No Abstract] [Full Text] [Related]
5. The evaluation of interferon lambda 4 rs368234815 as a predictor factor in treated patients with chronic hepatitis C genotype 1a infection.
Jalilian S; Latifi SM; Makvandi M; Teimoori A; Azaran A; Parsanahad M; Kayedani G
Indian J Med Microbiol; 2017; 35(2):262-268. PubMed ID: 28681817
[TBL] [Abstract][Full Text] [Related]
6. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.
Eslam M; Hashem AM; Leung R; Romero-Gomez M; Berg T; Dore GJ; Chan HL; Irving WL; Sheridan D; Abate ML; Adams LA; Mangia A; Weltman M; Bugianesi E; Spengler U; Shaker O; Fischer J; Mollison L; Cheng W; Powell E; Nattermann J; Riordan S; McLeod D; Armstrong NJ; Douglas MW; Liddle C; Booth DR; George J; Ahlenstiel G;
Nat Commun; 2015 Mar; 6():6422. PubMed ID: 25740255
[TBL] [Abstract][Full Text] [Related]
7. The Impact of interferon lambda 3 Polymorphism on Hepato-Cellular Carcinoma Progression in Hepatitis C Virus Patients: Treatment-Naïve and Experienced.
Abd Elrahman M; Ibrahim MK; Khairy A; Yosry A; Zayed N; Tawefeek S; Barakat AZ; Elbatae H; Bader El Din NG
Asian Pac J Cancer Prev; 2023 Jan; 24(1):215-221. PubMed ID: 36708570
[TBL] [Abstract][Full Text] [Related]
8. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
Murakawa M; Asahina Y; Kawai-Kitahata F; Nakagawa M; Nitta S; Otani S; Nagata H; Kaneko S; Asano Y; Tsunoda T; Miyoshi M; Itsui Y; Azuma S; Kakinuma S; Tanaka Y; Iijima S; Tsuchiya K; Izumi N; Tohda S; Watanabe M
J Med Virol; 2017 Jul; 89(7):1241-1247. PubMed ID: 28036111
[TBL] [Abstract][Full Text] [Related]
9. Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C.
Wróblewska A; Bernat A; Woziwodzka A; Markiewicz J; Romanowski T; Bielawski KP; Smiatacz T; Sikorska K
Clin Exp Med; 2017 May; 17(2):225-232. PubMed ID: 27125837
[TBL] [Abstract][Full Text] [Related]
10. Association of interferon lambda-4 rs12979860 polymorphism with hepatocellular carcinoma in patients with chronic hepatitis C infection.
de Bitencorte JT; Rech TF; Lunge VR; Dos Santos DC; Álvares-da-Silva MR; Simon D
World J Hepatol; 2021 Jan; 13(1):109-119. PubMed ID: 33584990
[TBL] [Abstract][Full Text] [Related]
11. Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study.
Noureddin M; Rotman Y; Zhang F; Park H; Rehermann B; Thomas E; Liang TJ
Genes Immun; 2015; 16(5):321-9. PubMed ID: 26020282
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of cirrhosis in patients with chronic hepatitis C genotype 4: Role of ABCB11 genotype polymorphism and plasma bile acid levels.
Besheer T; Arafa M; El-Maksoud MA; Elalfy H; Hasson A; Zalata K; Elkashef W; Elshahawy H; Raafat D; Elemshaty W; Elsayed E; Zaghloul H; Razek AA; El-Bendary M
Turk J Gastroenterol; 2018 May; 29(3):299-307. PubMed ID: 29755014
[TBL] [Abstract][Full Text] [Related]
13. Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease.
Petta S; Valenti L; Tuttolomondo A; Dongiovanni P; Pipitone RM; Cammà C; Cabibi D; Di Marco V; Fracanzani AL; Badiali S; Nobili V; Fargion S; Grimaudo S; Craxì A
Hepatology; 2017 Dec; 66(6):1885-1893. PubMed ID: 28741298
[TBL] [Abstract][Full Text] [Related]
14. Donor IFNL4 Genotype Is Associated with Early Post-Transplant Fibrosis in Recipients with Hepatitis C.
Aiken T; Garber A; Thomas D; Hamon N; Lopez R; Konjeti R; McCullough A; Zein N; Fung J; Askar M; John BV
PLoS One; 2016; 11(11):e0166998. PubMed ID: 27875564
[TBL] [Abstract][Full Text] [Related]
15. Effect of Vitamin D Serum Levels and GC Gene Polymorphisms in Liver Fibrosis Due to Chronic Hepatitis C.
Azevedo LA; Matte U; Silveira TR; Bonfanti JW; Bruch JP; Álvares-da-Silva MR
Ann Hepatol; 2017; 16(5):742-748. PubMed ID: 28809744
[TBL] [Abstract][Full Text] [Related]
16. Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus.
Sy A; McCabe L; Hudson E; Ansari AM; Pedergnana V; Lin SK; Santana S; Fiorino M; Ala A; Stone B; Smith M; Nelson M; Barclay ST; McPherson S; Ryder SD; Collier J; Barnes E; Walker AS; Pett SL; Cooke G;
PLoS One; 2023; 18(1):e0280551. PubMed ID: 36689413
[TBL] [Abstract][Full Text] [Related]
17. Extracellular Matrix Proteins Substantiate IL-28B T allele Effect on Histological Outcome of Chronic Hepatitis C.
Attallah AM; Omran D; Omran MM; Abdelrazek MA; Zayed R; Essawey RE; Saif S; Farid A; Hassany M; Yosry A; Omar A
Ann Hepatol; 2018 July - August ,; 17(4):569-576. PubMed ID: 29893697
[TBL] [Abstract][Full Text] [Related]
18. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.
Li JH; Lao XQ; Tillmann HL; Rowell J; Patel K; Thompson A; Suchindran S; Muir AJ; Guyton JR; Gardner SD; McHutchison JG; McCarthy JJ
Hepatology; 2010 Jun; 51(6):1904-11. PubMed ID: 20235331
[TBL] [Abstract][Full Text] [Related]
19. Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C.
Macaluso FS; Maida M; Cammà C; Cabibbo G; Cabibi D; Alduino R; Di Marco V; Craxì A; Petta S
J Hepatol; 2014 Sep; 61(3):523-9. PubMed ID: 24815874
[TBL] [Abstract][Full Text] [Related]
20. Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study.
Mechie NC; Goralzcyk AD; Reinhardt L; Mihm S; Amanzada A
BMC Res Notes; 2015 Jun; 8():260. PubMed ID: 26109044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
